Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 11/20 | 0.59 |
| ▸ | MAOB | P27338 | 7/20 | 0.56 |
| ▸ | MAOA | P21397 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | CALML3 | P27482 | 1/20 | 0.55 |
| ▸ | SDHA | P31040 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7710117 | 0.92 | F10 (0.60) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL7710113 | 0.92 | F10 (0.60) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL7707330 | 0.91 | F10 (0.62) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL7707326 | 0.91 | F10 (0.62) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL6158660 | 0.90 | F10 (0.71) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL6158654 | 0.90 | F10 (0.71) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL6040349 | 0.88 | F10 (0.58) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL6040546 | 0.88 | F10 (0.63) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL7710162 | 0.87 | MAOB (0.61) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL6040691 | 0.87 | MAOB (0.63) | F10MAOBMAOALMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1263742-B1 | OXAZOLIDINONE THIOAMIDES WITH PIPERAZINE AMIDE SUBSTITUENTS | PHARMACIA & UPJOHN CO LLC (US) | 2005-08-24 | — | — | EP | claimed |
| US-6642238-B2 | Microbiocides against grampositive and gramnegative bacteria | PHARMACIA AND UPJOHN COMPANY | 2003-11-04 | — | — | US | claimed |
| EP-1263742-A1 | OXAZOLIDINONE THIOAMIDES WITH PIPERAZINE AMIDE SUBSTITUENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-12-11 | — | — | EP | claimed |
| US-20020137754-A1 | Microbiocides against grampositive and gramnegative bacteria | PHARMACIA & UPJOHN COMPANY | 2002-09-26 | — | — | US | claimed |
| US-20010047004-A1 | Oxazolidinone thioamides with piperazine amide substituents | PHARMACIA & UPJOHN COMPANY | 2001-11-29 | — | — | US | claimed |
| WO-2001058885-A1 | OXAZOLIDINONE THIOAMIDES WITH PIPERAZINE AMIDE SUBSTITUENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-08-16 | — | — | WO | claimed |
| US-7049443-B2 | Amide-containing compound having improved solubility and method of improving the solubility of an amide-containing compound | PHARMACIA & UPJOHN COMPANY (US) | 2006-05-23 | — | — | US | disclosed |
| EP-1263742-B1 | OXAZOLIDINONE THIOAMIDES WITH PIPERAZINE AMIDE SUBSTITUENTS | PHARMACIA & UPJOHN CO LLC (US) | 2005-08-24 | — | — | EP | disclosed |
| US-20040014967-A1 | Amide-containing compound having improved solubility and method of improving the solubility of an amide-containing compound | PHARMACIA & UPJOHN COMPANY | 2004-01-22 | — | — | US | disclosed |
| US-6642238-B2 | Microbiocides against grampositive and gramnegative bacteria | PHARMACIA AND UPJOHN COMPANY | 2003-11-04 | — | — | US | disclosed |
| EP-1263742-A1 | OXAZOLIDINONE THIOAMIDES WITH PIPERAZINE AMIDE SUBSTITUENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020137754-A1 | Microbiocides against grampositive and gramnegative bacteria | PHARMACIA & UPJOHN COMPANY | 2002-09-26 | — | — | US | disclosed |
| US-20010047004-A1 | Oxazolidinone thioamides with piperazine amide substituents | PHARMACIA & UPJOHN COMPANY | 2001-11-29 | — | — | US | disclosed |
| WO-2001058885-A1 | OXAZOLIDINONE THIOAMIDES WITH PIPERAZINE AMIDE SUBSTITUENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137754-A1 | Microbiocides against grampositive and gramnegative bacteria | TLR1, MPO, TLR9 | F10 4072/4885MAOB 1587/4885MAOA 1130/4885 |
| US-20010047004-A1 | Oxazolidinone thioamides with piperazine amide substituents | OXA1L, HDAC1, TOP2A | F10 4617/4885MAOB 4053/4885MAOA 3752/4885 |
| US-20040014967-A1 | Amide-containing compound having improved solubility and method of improving the solubility of an amide-containing compound | AADAC, AAAS, SLC7A1 | F10 2380/4885MAOB 732/4885MAOA 1179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.